HKSTP Crowns Overall Champion Skyland Innovation at EPiC 2023 Pitching Competition Beating Over 610 Global Startups
28.4.2023 18:11:00 EEST | Business Wire | Press release
Hong Kong Science and Technology Parks Corporation (HKSTP) today successfully held its 7th Elevator Pitch Competition (EPiC), naming Hong Kong startup, Skyland Innovation, as the overall 2023 champion, beating over 610 startups from 55 economies around the world. The signature event has partnered with the city’s leading corporations: Cathay, HSBC, MTR Lab, plus global accelerator Plug & Play, to become a true iconic mega event that has hit a global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230428005353/en/
Mr Albert Wong, CEO of HKSTP (Centre), alongside EPiC 2023 Top 10 overall finalists. (Photo: Business Wire)
As Hong Kong’s flagship and largest pitching contest, 50 Grand Finale semi-finalists joined the city’s most eagerly anticipated pitch event this year at sky100 at the top of the International Commerce Centre in West Kowloon to re-create a real-life 60-second elevator pitch experience.
The EPiC 2023 judging panel of the region’s top entrepreneurs, investors and innovation ecosystem leaders selected Skyland Innovation from Hong Kong, as this year’s overall champion. The winner of the grand prize of US$ 90,000, helps property owners and contractors to coordinate and communicate seamlessly on construction sites through the use of robotics and AI. The local proptech is also a spinoff from the Hong Kong Center for Construction Robotics (HKCRC) within the HKSAR Government backed AIR@InnoHK research cluster located at Hong Kong Science Park.
Along with all 50 semi-finalists, Skyland Innovation also qualifies to be considered by the HKSTP Venture Fund for additional investment deals. If selected, each company can potentially receive up to a maximum investment of US$5 million.
EPiC 2023 competitors were split across the two themes of FinTech and PropTech with FinCrime Dynamics from the UK named as the overall FinTech category winner, and Skyland Innovation Company Ltd named the overall PropTech winner from Hong Kong. This year, Canvasland, a FinTech startup from Hong Kong was also voted by the public as the “My Favourite Pitcher" winner, taking away US$10,000 and 200,000 Asia Miles. The top 10 overall finalists also won US$10,000 each (Full winners and finalists list below).
Paul Chan, Financial Secretary of Hong Kong SAR, said: “Hong Kong has a strong, thriving startup ecosystem with 4000 startups, up more than 50% from 2018. Hong Kong is also a natural gateway to the GBA, which offers tremendous growth opportunities. Successful products and services will surely have an edge in the GBA, the whole of the nation and around the world. I am truly excited to be here at EPiC 2023 where startups strive to make their 60-second pitch truly count. I congratulate all the EPiC 2023 winners and invite startups from all over the world to join us in Hong Kong where the future is built.”
Sunny Chai, Chairman, HKSTP, said: “EPiC 2023 showcases the most exciting innovations from the world’s star-studded next-generation global tech ventures. Together with the Hong Kong Government's solid commitment, as reinforced by the Hong Kong I&T Development Blueprint, our city provides the ideal platform to expand into the vast Asian market. Hong Kong is also Asia’s world city and a bridge between the mainland and the world, making us a magnet for global innovation talent and enterprises.”
Albert Wong, CEO, HKSTP, said: “This year’s EPiC competition features a record international turnout and shows Hong Kong is truly back with a strong show of unicorns and soonicorns from around the world among this year’s finalists. But EPiC is more than just a competition, it is a prime example of Hong Kong’s unique ability to help startups grow fast and go beyond by providing a network of global investment opportunities and innovation talent to turn cutting-edge science, technologies, and ideas into game-changing solutions."
A magnet for global investors and innovation talent
EPiC 2023 surpassed all expectations, attracting over 610 entries from 55 countries and cities across five continents. Over 75% of contestants come from overseas, a record high proportion of overseas contestants and economies participation since 2016. Startups joining EPiC 2023 can fully leverage the largest I&T ecosystem in Hong Kong and HKSTP’s direct connections to over 1,000 investors and more than 300 corporate partners.
In addition to the EPiC final pitching contest, the 50 semi-finalists have also taken part in the "Grow Beyond Hong Kong" Immersion Programme. This exclusive 2-day programme ran from 25-26 April, immersed the EPiC 2023 semi-finalists directly into HKSTP’s innovation ecosystem. Participants will unlock growth opportunities through educational talks, business matching and networking with leading corporate partners and investors in our ecosystem.
Winners List:
|
Overall Champion |
Skyland Innovation Company Ltd. |
||
|
“My Favourite Pitcher” Winner |
Canvasland Limited |
||
|
FinTech Winner |
FinCrime Dynamics |
||
|
PropTech Winner |
Skyland Innovation Company Ltd. |
||
|
Top 10 Overall Finalists |
FinTech Finalists:
FinCrime Dynamics Homebase Ultipa VoiceAI Technologies
PropTech Finalists:
I2Cool Limited
Mimicrete VoltSafe, Inc. Skyland Innovation Company Ltd. |
Contestants Breakdown:
|
Category |
|
|
No. of applicants |
|
PropTech |
|
|
266 (43%) |
|
FinTech |
|
|
352 (57%) |
|
|
|
|
|
|
|
|
|
No. of applicants |
|
Overseas |
|
|
465 (75%) |
|
Hong Kong |
|
|
153 (25%) |
A record high proportion of overseas contestants and economies participation since 2016.
For more information on EPiC 2023, please visit: https://epic.hkstp.org/
About Hong Kong Science and Technology Parks Corporation
Hong Kong Science and Technology Parks Corporation (HKSTP) has for over 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to two unicorns and Hong Kong’s leading R&D hub with over 13,000 research professionals and over 1,300 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.
Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern INNOPARKs in Tai Po, Tseung Kwan O and Yuen Long. The three INNOPARKs are realising a vision of new industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.
Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.
More information about HKSTP is available at www.hkstp.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230428005353/en/
Contact information
Media Contact:
Hong Kong Science and Technology Parks Corporation
Betsy Leung
Tel: +852 2629 2300
Email: betsy.leung@hkstp.org
Edelman Public Relations
Lisa Tse
Tel: +852 3756 8632 / 6347 2009
Email: Lisa.Tse@edelman.com / Edelmanhkstppr@edelman.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom